# An Phase I Study of YY001 in Patients with Advanced Solid Tumors

> **NCT06228846** · PHASE1 · COMPLETED · sponsor: **Shanghai Yuyao Biotech Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** YY001

## Key facts

- **NCT ID:** NCT06228846
- **Lead sponsor:** Shanghai Yuyao Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-14
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06228846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06228846, "An Phase I Study of YY001 in Patients with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06228846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*